Auswahl der wissenschaftlichen Literatur zum Thema „Digestive cancers“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Digestive cancers" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Digestive cancers"

1

Zhang, Tao, Bofang Wang, Baohong Gu, et al. "Genetic and Molecular Characterization Revealed the Prognosis Efficiency of Histone Acetylation in Pan-Digestive Cancers." Journal of Oncology 2022 (April 5, 2022): 1–21. http://dx.doi.org/10.1155/2022/3938652.

Der volle Inhalt der Quelle
Annotation:
The imbalance between acetylation and deacetylation of histone proteins, important for epigenetic modifications, is closely associated with various diseases, including cancer. However, knowledge regarding the modification of histones across the different types of digestive cancers is still lacking. The purpose of this research was to analyze the role of histone acetylation and deacetylation in pan-digestive cancers. We systematically characterized the molecular alterations and clinical relevance of 13 histone acetyltransferase (HAT) and 18 histone deacetylase (HDAC) genes in five types of digestive cancers, including esophageal carcinoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer. Recurrent mutations and copy number variation (CNV) were extensively found in acetylation-associated genes across pan-digestive cancers. HDAC9 and KAT6A showed widespread copy number amplification across five pan-digestive cancers, while ESCO2, EP300, and HDAC10 had prevalent copy number deletions. Accordingly, we found that HAT and HDAC genes correlated with multiple cancer hallmark-related pathways, especially the histone modification-related pathway, PRC2 complex pathway. Furthermore, the expression pattern of HAT and HDAC genes stratified patients with clinical benefit in hepatocellular carcinoma and pancreatic cancer. These results indicated that acetylation acts as a key molecular regulation of pan-digestive tumor progression.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Yang, Ting-Fang, Xin-Rui Li, and Mo-Wei Kong. "Molecular mechanisms underlying roles of long non-coding RNA small nucleolar RNA host gene 16 in digestive system cancers." World Journal of Gastrointestinal Oncology 16, no. 11 (2024): 4300–4308. http://dx.doi.org/10.4251/wjgo.v16.i11.4300.

Der volle Inhalt der Quelle
Annotation:
This editorial reviews the molecular mechanisms underlying the roles of the long non-coding RNA (lncRNA) small nucleolar RNA host gene 16 (SNHG16 ) in digestive system cancers based on two recent studies on lncRNAs in digestive system tumors. The first study, by Zhao et al , explored how hBD-1 affects colon cancer, via the lncRNA TCONS_00014506 , by inhibiting mTOR and promoting autophagy. The second one, by Li et al , identified the lncRNA prion protein testis specific (PRNT ) as a factor in oxaliplatin resistance by sponging ZNF184 to regulate HIPK2 and influence colorectal cancer progression and chemoresistance, suggesting PRNT as a potential therapeutic target for colorectal cancer. Both of these two articles discuss the mechanisms by which lncRNAs contribute to the development and progression of digestive system cancers. As a recent research hotspot, SNHG16 is a typical lncRNA that has been extensively studied for its association with digestive system cancers. The prevailing hypothesis is that SNHG16 participates in the development and progression of digestive system tumors by acting as a competing endogenous RNA, interacting with other proteins, regulating various genes, and affecting downstream target molecules. This review systematically examines the recently reported biological functions, related molecular mechanisms, and potential clinical significance of SNHG16 in various digestive system cancers, and explores the relationship between SNHG16 and digestive system cancers. The findings suggest that SNHG16 may serve as a potential biomarker and therapeutic target for human digestive system cancers.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Stokłosa, Paulina, Anna Borgström, Sven Kappel, and Christine Peinelt. "TRP Channels in Digestive Tract Cancers." International Journal of Molecular Sciences 21, no. 5 (2020): 1877. http://dx.doi.org/10.3390/ijms21051877.

Der volle Inhalt der Quelle
Annotation:
Cancers of the digestive tract are among the most prevalent types of cancer. These types of cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently, many biomedical studies focus on the role of ion channels, in particular transient receptor potential (TRP) channels, in cancer pathophysiology. TRP channels show mostly non-selective permeability to monovalent and divalent cations. TRP channels are often dysregulated in digestive tract cancers, which can result in alterations of cancer hallmark functions, such as enhanced proliferation, migration, invasion and the inability to induce apoptosis. Therefore, TRP channels could serve as potential diagnostic biomarkers. Moreover, TRP channels are mostly expressed on the cell surface and ion channel targeting drugs do not need to enter the cell, making them attractive candidate drug targets. In this review, we summarize the current knowledge about TRP channels in connection to digestive tract cancers (oral cancer, esophageal cancer, liver cancer, pancreatic cancer, gastric cancer and colorectal cancer) and give an outlook on the potential of TRP channels as cancer biomarkers or therapeutic targets.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Zhang, Nan, Yueying Wang, Gary Tse, Guangping Li, Shouling Wu, and Tong Liu. "Association of Visit-to-Visit Variability in Fasting Plasma Glucose with Digestive Cancer Risk." Oxidative Medicine and Cellular Longevity 2022 (July 13, 2022): 1–12. http://dx.doi.org/10.1155/2022/4530894.

Der volle Inhalt der Quelle
Annotation:
Background and Aims. The aim of this study is to investigate the association between visit-to-visit variability in fasting plasma glucose (FPG) and the risk of digestive cancers among individuals with and without diabetes. Methods. Using data from Kailuan cohort, a prospective population-based study, individuals who had at least two measurements of FPG between 2006 and 2012 without prior cancer were included in this study. Four indexes of variability were used, including standard deviation (SD), coefficient of variation (CV), variability independent of the mean (VIM), and average successive variability (ARV). Cox regression was used to evaluate the relationship between the quartiles of FPG variability and digestive cancers. Results. A total of 98,161 individuals were studied. Over a mean follow-up of 9.32 ± 0.81 years, 1103 individuals developed incident digestive cancer (1.21 per 1000 person-years). Compared to the individuals in the lowest quartile, those in the highest quartile of FPG variability by SD had 38.7% higher risk of developing overall digestive cancers after adjusting for the significant confounders (hazard ratio, 1.387; 95% confidence interval, 1.160-1.659; P = 0.0003 ). Higher FPG variability was associated with significantly higher risks of colorectal cancer (fully adjusted HR 1.432, 95% CI [1.073-1.912], P = 0.015 ) and pancreatic cancer (fully adjusted HR 2.105, 95% CI [1.024-4.329], P = 0.043 ), but not liver cancer (fully adjusted HR 1.427, 95% CI [0.973-2.092], P = 0.069 ) or esophageal and gastric cancer (fully adjusted HR 1.139, 95% CI [0.776-1.670], P = 0.506 ). Subgroup analyses showed that individuals who were younger (<65 years), male, and those without diabetes experienced a predominantly higher risk of developing digestive cancers. Similar results were observed when using CV, VIM, and ARV. Conclusions. FPG variability was significantly associated with increasing risk of digestive cancers, especially for pancreatic and colorectal cancer. Our study suggested a potential role of FPG variability in risk stratification of digestive cancers. Approaches that reduce FPG variability may lower the risks of incident digestive cancers among the general population. This trial is registered with ChiCTR-TNRC-11001489.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Ishikawa, Marin, Kohei Nakamura, Ryutaro Kawano, et al. "Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan." Cancers 16, no. 8 (2024): 1504. http://dx.doi.org/10.3390/cancers16081504.

Der volle Inhalt der Quelle
Annotation:
The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers. Patients with various cancer types recruited between March 2020 and October 2022 underwent the FoundationOne® CDx assay at the Keio PleSSision Group (19 hospitals in Japan). A scoring system was developed to identify potentially actionable genomic alterations of biological significance and actionable genomic alterations. The detection rates for potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to companion diagnosis (CDx), as well as the signaling pathways associated with these alterations in each digestive cancer, were analyzed. Among the 1587 patients, 547 had digestive cancer. The detection rates of potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to CDx were 99.5%, 62.5%, and 11.5%, respectively. APC, KRAS, and CDKN2A alterations were frequently observed in colorectal, pancreatic, and biliary cancers, respectively. Most digestive cancers, except esophageal cancer, were adenocarcinomas. Thus, the classification flowchart for digestive adenocarcinomas proposed in this study may facilitate precise diagnosis. CGP has clinical and diagnostic utility in digestive cancers.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Capparelli, Rosanna, Paola Cuomo, Antonio Gentile, and Domenico Iannelli. "Microbiota–Liver Diseases Interactions." International Journal of Molecular Sciences 24, no. 4 (2023): 3883. http://dx.doi.org/10.3390/ijms24043883.

Der volle Inhalt der Quelle
Annotation:
Gut microbiota regulates essential processes of host metabolism and physiology: synthesis of vitamins, digestion of foods non-digestible by the host (such as fibers), and—most important—protects the digestive tract from pathogens. In this study, we focus on the CRISPR/Cas9 technology, which is extensively used to correct multiple diseases, including liver diseases. Then, we discuss the non-alcoholic fatty liver disease (NAFLD), affecting more than 25% of the global population; colorectal cancer (CRC) is second in mortality. We give space to rarely discussed topics, such as pathobionts and multiple mutations. Pathobionts help to understand the origin and complexity of the microbiota. Since several types of cancers have as target the gut, it is vital extending the research of multiple mutations to the type of cancers affecting the gut–liver axis.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Reitano, Elisa, Nicola de’Angelis, Paschalis Gavriilidis, et al. "Oral Bacterial Microbiota in Digestive Cancer Patients: A Systematic Review." Microorganisms 9, no. 12 (2021): 2585. http://dx.doi.org/10.3390/microorganisms9122585.

Der volle Inhalt der Quelle
Annotation:
The relation between the gut microbiota and human health is increasingly recognized. Recently, some evidence suggested that dysbiosis of the oral microbiota may be involved in the development of digestive cancers. A systematic review was conducted according to the PRISMA guidelines to investigate the association between the oral microbiota and digestive cancers. Several databases including Medline, Scopus, and Embase were searched by three independent reviewers, without date restriction. Over a total of 1654 records initially identified, 28 studies (2 prospective cohort studies and 26 case-controls) were selected. They investigated oral microbiota composition in patients with esophageal squamous cell carcinoma (n = 5), gastric cancer (n = 5), colorectal cancer (n = 9), liver carcinoma (n = 2), and pancreatic cancer (n = 7). In most of the studies, oral microbiota composition was found to be different between digestive cancer patients and controls. Particularly, oral microbiota dysbiosis and specific bacteria, such as Fusobacterium nucleatum and Porphyromonas gingivalis, appeared to be associated with colorectal cancers. Current evidence suggests that differences exist in oral microbiota composition between patients with and without digestive cancers. Further studies are required to investigate and validate oral–gut microbial transmission patterns and their role in digestive cancer carcinogenesis.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Turati, Federica, Marta Rossi, Claudio Pelucchi, Fabio Levi, and Carlo La Vecchia. "Fruit and vegetables and cancer risk: a review of southern European studies." British Journal of Nutrition 113, S2 (2015): S102—S110. http://dx.doi.org/10.1017/s0007114515000148.

Der volle Inhalt der Quelle
Annotation:
High intakes of fruit and vegetables may reduce the risk of cancer at several sites. Evidence has been derived mainly from case–control studies. We reviewed the relationship between consumption of vegetables and fruit and the risk of several common cancers in a network of Italian and Swiss case–control studies including over 10 000 cases of fourteen different cancers and about 17 000 controls. Data were suggestive of a protective role of vegetable intake on the risk of several common epithelial cancers. OR for the highest compared with the lowest levels of consumption ranged from 0·2 (larynx, oral cavity and pharynx) to 0·9 (prostate). Inverse associations were found for both raw and cooked vegetables, although for upper digestive tract cancers the former were somewhat stronger. Similar inverse associations were found for cruciferous vegetables. Frequent consumption of allium vegetables was also associated with reduced risk of several cancers. Fruit was a favourable correlate of the risk of several cancers, particularly of the upper digestive tract, with associations generally weaker than those reported for vegetables. A reduced risk of cancers of the digestive tract and larynx was found for high consumption of citrus fruit. Suggestive protections against several forms of cancer, mainly digestive tract cancers, were found for high consumption of apples and tomatoes. High intakes of fibres, flavonoids and proanthocyanidins were inversely related to various forms of cancer. In conclusion, data from our series of case–control studies suggested a favourable role of high intakes of fruit and vegetables in the risk of many common cancers, particularly of the digestive tract. This adds evidence to the indication that aspects of the Mediterranean diet may have a favourable impact not only on CVD, but also on several common (epithelial) cancers, particularly of the digestive tract.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Xiong, Zuming, Yongjun Yang, Wenxin Li, Yirong Lin, Wei Huang, and Sen Zhang. "Exploring Key Biomarkers and Common Pathogenesis of Seven Digestive System Cancers and Their Correlation with COVID-19." Current Issues in Molecular Biology 45, no. 7 (2023): 5515–33. http://dx.doi.org/10.3390/cimb45070349.

Der volle Inhalt der Quelle
Annotation:
Digestive system cancer and COVID-19 significantly affect the digestive system, but the mechanism of interaction between COVID-19 and the digestive system cancers has not been fully elucidated. We downloaded the gene expression of COVID-19 and seven digestive system cancers (oral, esophageal, gastric, colorectal, hepatocellular, bile duct, pancreatic) from GEO and identified hub differentially expressed genes. Multiple verifications, diagnostic efficacy, prognostic analysis, functional enrichment and related transcription factors of hub genes were explored. We identified 23 common DEGs for subsequent analysis. CytoHubba identified nine hub genes (CCNA2, CCNB1, CDKN3, ECT2, KIF14, KIF20A, KIF4A, NEK2, TTK). TCGA and GEO data validated the expression and excellent diagnostic and prognostic ability of hub genes. Functional analysis revealed that the processes of cell division and the cell cycle were essential in COVID-19 and digestive system cancers. Furthermore, six related transcription factors (E2F1, E2F3, E2F4, MYC, TP53, YBX1) were involved in hub gene regulation. Via in vitro experiments, CCNA2, CCNB1, and MYC expression was verified in 25 colorectal cancer tissue pairs. Our study revealed the key biomarks and common pathogenesis of digestive system cancers and COVID-19. These may provide new ideas for further mechanistic research.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Adianto Nugroho, Fransicus Arifin, Perwira Widianto, et al. "Digestive Surgery Services in COVID-19 Pandemic Period: Indonesian Society of Digestive Surgeons Position Statement." Journal Of The Indonesian Medical Association 70, no. 6 (2020): 132–41. http://dx.doi.org/10.47830/jinma-vol.70.6-2020-239.

Der volle Inhalt der Quelle
Annotation:
Digestive surgery service including surgical management of gastrointestinal disease and digestive cancers are experiencing the impact of COVID-19 pandemic. Therefore it is necessary to formulate recommendation for digestives surgery service, as guidelines to engage in case-by-case assessment of particular patients with digestive diseases. We are aware that the knowledge and science of COVID-19 are still evolving, with new progression every day. This recommendation reflect actual condition and are subject for future adjustment in the future.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Digestive cancers"

1

Le, Scanf Enora. "Caractérisation des altérations de l’épissage des ARN pré-messagers dans les cancers digestifs à microsatellites instables." Electronic Thesis or Diss., Brest, 2024. http://www.theses.fr/2024BRES0113.

Der volle Inhalt der Quelle
Annotation:
L’exon en aval dans l’ARNm, dépendant du gène considéré et de la taille de la délétion dans le SP-MS. Nous montrons qu’un SP-MS raccourci présente moins d’affinité pour la protéine U2AF2 in vitro et que la mutation U2AF1-S34F ou le knock-down d’U2AF1 peuvent mimer l’effet de l’altération du PyT. Enfin, les transcrits matures dépourvus de l'exon cible peuvent être soit stables, soit dégradés par le système NMD de surveillance des codons non-sens prématurés, et ne sont donc pas dotés d'une capacité spécifique à éviter la dégradation. Nous supposons que les protéines aberrantes, qui peuvent être traduites à partir de ces ARNm alternatifs, pourraient participer à l’oncogenèse par la production de néo-antigènes associés aux tumeurs<br>Gastric and colorectal cancers are among the most common and deadly cancers. The MSI (Microsatellite Instability) subtype, which accounts for 15-20% of these cancers is deficient in the DNA mismatch repair system, thus leading to microsatellite instability. The polypyrimidine tract (SP-MS) that seats at the 3’ end of the intron, can be considered as a microsatellite-like structure that participates to the splicing of the downstream exon by interacting mainly with the U2AF2 protein and forms a heterodimer with the U2AF1 protein, which recognizes the AG dinucleotide 3’ acceptor splice site. Shortening of the PyT, in MSI cancers, can lead to splicing changes. We have identified a massive alteration of pre-messenger RNA splicing in digestive MSI cancers, in association with SP-MS shortening. These splicing defects are characterized by downstream exon skipping in mRNA, depending both on the gene considered and the size of the deletion in the SP-MS. We showed that a shortened SP-MS has less affinity for the U2AF2 protein in vitro and the mutation or knock-down of U2AF1 can mimic the effect of SP-MS alterations. Finally, mature transcripts devoid of the target exon can be either stable or degraded by the nonsense-mediated mRNA decay surveillance mechanism, and thus, are not endowed with a specific ability to avoid degradation. We surmise that the aberrant proteins that may be translated from these alternative mRNAs could participate in oncogenic mechanisms through the production of tumour-associated neo-antigens
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Macaire, Pauline. "Modélisation par une approche de population de l’effet des facteurs de croissance granulocytaire lors de neutropénies chimio-induites." Thesis, Bourgogne Franche-Comté, 2020. http://www.theses.fr/2020UBFCJ001.

Der volle Inhalt der Quelle
Annotation:
Les travaux de cette thèse s'appuient sur les résultats d'une étude de cohorte ayant pour objectif principal de définir le schéma optimal d'administration prophylactique des facteurs de croissance granulocytaire (G-CSF) dans le cadre d’un traitement par FOLFIRINOX. Pour ce faire, un modèle pharmacocinétique/pharmacodynamique (PK/PD) a été construit pour décrire l'évolution des polynucléaires neutrophiles (PNN) en fonction du temps dans notre population en tenant compte de l'effet neutropéniant des trois chimiothérapies administrées mais également de l'effet stimulant des G-CSF exogènes sur la prolifération et la maturation des neutrophiles. Sur la base des estimations des paramètres du modèle obtenus, des simulations ont été réalisées afin de déterminer l'incidence et la durée des neutropénies pour chaque schéma prophylactique de G-CSF selon le début, la durée mais également la nature du traitement (formulation pegylée ou non). Pour réaliser ces simulations, la valeur initiale en PNN avant le début du cycle de chimiothérapie a été considérée; en cas de concentration initiale élevée (&gt; 6,5 G/L), l'utilisation d'un traitement prophylactique ne semble pas nécessaire du fait d'un risque de neutropénie limitée. Par ailleurs, pour les patients dont la concentration initiale en PNN se situe en dessous de 6,5 G/L, au vu de nos résultats, une administration unique de peg-G-CSF 24 heures après la fin de la perfusion de 5-FU de 46 heures semble le schéma prophylactique le plus approprié pour réduire l'incidence et la durée des neutropénies induites par le FOLFIRINOX. Néanmoins, contrairement aux idées reçues, l'augmentation de la durée d'injections quotidiennes de G-CSF ou une administration tardive des facteurs de croissance granulocytaire n'est pas forcément profitable pour les patients du fait de l'augmentation de l'incidence des neutropénies sévères par rapport à la non-administration de traitement prophylactique<br>The work of this thesis is based on results of a cohort study whose main objective was to define the optimal schedule of prophylactic administration of granulocyte growth factors (G-CSF) in the context of FOLFIRINOX treatment. For this purpose, a pharmacokinetic/pharmacodynamic (PK/PD) model was built to describe the absolute neutrophil counts (ANC) time course in our population, including the three chemotherapies neutropenic effect, but also the stimulating effect of exogenous G-CSF on the proliferation and maturation of neutrophils. Based on the estimates of the model parameters, simulations were performed to determine the incidence and duration of neutropenia for each prophylactic G-CSF schedule depending on the begining, the duration but also the nature of the treatment (pegylated formulation or not). The pre-therapeutic ANC value was considered; in case of high initial ANC (&gt; 6.5 G/L), the use of prophylactic treatment does not seems necessary due to the limited risk of neutropenia. Furthermore, for patients whose initial ANC is below 6.5 G/L, based on our results, a single administration of peg-G-CSF 24 hours after the end of the 46 hours 5-FU infusion seems to be the most appropriate prophylactic schedule to reduce the incidence and the duration of FOLFIRINOX-induced neutropenia. However, contrary to popular belief, increasing the number of daily G-CSF injections or late administration of G-CSF is not necessarily beneficial for patients due to the increased incidence of severe neutropenia compared to the absence of treatment
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Väkeväinen, Satu. "Local acetaldehyde production as a pathogenetic factor for upper digestive tract cancers in humans." Helsinki : University of Helsinki, 2002. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/vakevainen/.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Vila, Casadesús Maria. "Design of bioinformatic tools for integrative analysis of microRNA-mRNA interactome applied to digestive cancers." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/663087.

Der volle Inhalt der Quelle
Annotation:
En esta tesis se han desarrollado e implementado distintas herramientas bioinformáticas que permiten el estudio de las interacciones miRNA-mRNA en contextos celulares específicos. oncretamente se ha creado un paquete de R (miRComb) que calcula las interacciones miRNA-mRNA partiendo de expresión de miRNAs y mRNAs, y predicciones bloinformáticas de bases de datos preexistentes. Las interacciones miRNA-mRNA finales son aquellas que muestran una correlación negativa y han estado predichas por al meno una base de datos. Como valor añadido, el paquete miRComb realiza un resumen en pdf con los resultados básicos del análisis (número de interacciones, número de mRNAs target por miRNA, análisis funcional, etc.), que permite comparar los datos de distintos estudios. Hemos aplicado esta metodología en el contexto de cánceres digestivos. En un primer estudio hemos utilizado datos públicos de 5 cánceres digestivos (colon, recto, esófago, stómago e hígado) y hemos determinado las interacciones miRNA-mRNA comunes entre ellos y específicas de cada uno. En un segundo estudio, hemos utilizado la misma metodología para analizar datos de IRNA-mRNA en biopsias de pacientes del Hospital Clínic de Barcelona con cáncer de páncreas. En este estudio hemos descrito interacciones miRNA-mRNA en el contexto de cáncer pancreático y hemos podido validar dos de ellas a nivel experimental. En resumen, podemos concluir que el paquete miRComb es una herramienta útil para el estudio del interactoma de miRNA-mRNA, y que ha servido para establecer hipótesis biológicas que luego se han podido comprobar en el laboratorio.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Perrichet-Pechinez, Anaïs. "Ciblage de l'IL-1beta pour améliorer l'efficacité de la chimio-immunothérapie dans le cancer." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2024. http://www.theses.fr/2024UBFCI014.

Der volle Inhalt der Quelle
Annotation:
L'IL-1b est connue pour avoir un rôle ambivalent dans le microenvironnement tumoral. Le cancer du poumon et le cancer colorectal figurent parmi les cancers les plus meurtriers, et l'incidence de l'adénocarcinome canalaire pancréatique a considérablement augmenté au cours des 30 dernières années. Ce projet vise à étudier le rôle de l'IL-1b dans les cancers du poumon, du côlon et du pancréas en condition de traitement par chimio-immunothérapie et démontrer comment cette interleukine agit dans le microenvironnement tumoral afin d’identifier des pistes d’amélioration thérapeutique.Dans le cancer du poumon non à petites cellules, l'IL-1b a un rôle antitumoral en présence de chimio-immunothérapie, en participant au recrutement des cellules T CD8+ via la production de CXCL10 par les cellules cancéreuses. En revanche, dans les cancers digestifs tels que ceux du pancréas et du côlon, l'IL-1b joue un rôle pro-tumoral en favorisant l’immunosuppression dans le microenvironnement tumoral, augmentant ainsi la résistance aux traitements.Ainsi, la compréhension du rôle et des interactions spécifiques de l'IL-1b dans différents microenvironnements tumoraux pourrait offrir des perspectives pour développer des stratégies thérapeutiques ciblées et plus efficaces<br>IL-1β is known to have an ambivalent role in the tumor microenvironment. Lung cancer and colorectal cancer are among the deadliest cancers, and the incidence of pancreatic ductal adenocarcinoma has significantly increased over the past 30 years. This project aim to study the role of IL-1β in lung, colon, and pancreatic cancers in a context of chemo-immunotherapy, and investigate how this interleukin functions within the tumor microenvironment, to identify potential therapeutic improvements.In non-small cell lung cancer, IL-1β exhibits an antitumor role in the presence of chemoimmunotherapy by contributing to the recruitment of CD8+ T cells through the production of CXCL10 by cancer cells. Conversely, in digestive cancers such as pancreatic and colon cancers, IL-1β plays a pro-tumoral role by promoting immunosuppression within the tumor microenvironment, thereby increasing resistance to treatments.Thus, understanding the specific roles and interactions of IL-1β in different tumor microenvironments could offer insights for developing more targeted and efficient therapeutic strategies
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Cui, Yan. "Polymorphism of xeroderma pigmentosum group G and dietary flavonoid intake on the risk of lung and upper aero-digestive tract cancers." Diss., Restricted to subscribing institutions, 2005. http://proquest.umi.com/pqdweb?did=954047411&sid=1&Fmt=2&clientId=1564&RQT=309&VName=PQD.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Gupta, Bhawna. "Life-course approach to behavioural risk factors and quality of life for cancers of the upper aero-digestive tract in an Indian population: a case-control study." Thesis, Griffith University, 2018. http://hdl.handle.net/10072/371971.

Der volle Inhalt der Quelle
Annotation:
The incidence and mortality rates of cancers of upper aero-digestive tract (UADT) remain significantly high in India. These cancers, which occur more commonly in later adulthood, are influenced by social and lifestyle behaviours carried out during childhood, adolescence and early adult life. Thus, life-course epidemiology attempts to assess varying health effects of various risk factors, according to timing, duration and frequency of exposure, which may give important clues to the causes of cancer. These cancers have serious impacts on quality of life (QoL) as they involve anatomical structures essential for mastication, speaking, cosmetic appearance and psychological wellbeing. Moreover, these cancers frequently present late and progress rapidly. Therefore, there is a need to develop a model for cost-effective screening and detection of individuals at high-risk of these cancers in the near future as well as early detection of cancer cases. Thereby, a study was designed with the following hypotheses:  Early age at initiation, frequency and duration of use of tobacco in its all forms, exposure to second hand tobacco smoke (SHS) at home and drinking alcohol has a linear dose-response relationship with the incidence of UADT cancers.  There is an association between tobacco, alcohol drinking, diet, oral hygiene and anthropometry measures with incidence of oral cancers.  Cancer site, staging, gender and age at diagnosis have an impact on QoL.  A risk-factor based screening model for UADT cancers has strong predictive ability to detect high-risk individuals. A bi-centre hospital-based frequency matched case-control study was conducted in Pune, Maharashtra State, India, from June 2014 and May 2015. Cases were histopathologically confirmed new cases of squamous cell carcinoma of UADT. Controls were patients diagnosed with a disease other than UADT or any other cancer, selected from the same hospital during the same period as the cases were recruited. Data were collected by medical-record abstraction, face-face interviews and by visual inspection of the oral cavity. A closed-ended questionnaire with a life-course perspective was used to collect patient‟s self-reported information on sociodemographics, lifestyle habits (chewing and smoking tobacco, drinking alcohol, SHS, oral hygiene) and QoL. The interviewer recorded anthropometry measures and number of missing teeth. Unconditional logistic regression was used to estimate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs). A reciever-operater characterstic curve was plotted against sensitivity and false-positive rate to produce a cut off point for the presence of UADT cancers. Examination of all QoL domains was done using oneway analysis of variance and the Bonferroni adjustments for post-hoc comparisons. Data were analysed by the Statistical Package for Social Sciences version 22. A total of 480 patients participated in the study. Chewing tobacco emerged as the strongest predictor for UADT cancers (OR=7.61; 95% CI 4.65-12.45) followed by smoking and drinking alcohol. Exposure to SHS during childhood (<16 years) rather than after ≥16 years increased the risk significantly (OR=4.05; 95% CI 2.06-7.95). There is a linear dose-response relationship between duration, frequency and early age at initiation for lifestyle risk factors (chewing and smoking tobacco; drinking alcohol) with incidence of UADT cancers in adulthood. Combined effects of tobacco and alcohol consumption habits elevated the risk (OR=12.05; 95% CI 4.61-31.49) in comparison to never users of these habits. Furthermore, the combination of these three lifestyle risk factors accounted for 86.82% of population attributable risk. Overall, the most affected QoL domains were anxiety and mood both among cases and controls. Oropharynx and hypopharynx cancer cases had the worst mean scores across all QoL domains. Stage IV cancer patients showed the worst QoL. Amongst UADT cancers in Pune, cancer of the oral cavity was the most common. Chewing tobacco showed higher odds (OR=8.51; 95% CI 4.90-14.77) for oral cancer risk as compared to UADT cancers. Poor oral hygiene emerged as significant predictor for oral cancer risk (OR=6.98; 95% CI 3.72-13.05). A screening model was derived for detection of individuals at high-risk for UADT cancers. This model has high sensitivity (93.5%), specificity (71.1%), false positive rate (28.8%), false negative rate (6.4%), positive predictive value (74.8%) and negative predictive value (96.6%). Our research recognises the framework of life-course influences of early exposure to behavioural risk-factors as independent and combined predictors of UADT cancers. The significantly compromised QoL in UADT cancer needs to be incorporated as an outcome measure in an individualized approach to therapeutic and palliative care planning of these cases to enable a better quality of survival. If validated in other studies, our proposed screening model can be applicable to many other high-risk UADT cancer populations with behavioural risk factors similar to our study population.<br>Thesis (PhD Doctorate)<br>Doctor of Philosophy (PhD)<br>School of Dentistry and Oral Health and Menzies Health Institute Queensland<br>Griffith Health<br>Full Text
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Chen, Jun 1969. "The association between dietary intake and the risk of cancers of the upper aero-digestive tract : a case-control study in Brazil." Thesis, McGill University, 2002. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=29422.

Der volle Inhalt der Quelle
Annotation:
Cancers of the upper aero-digestive tract (UADT) rank as the fifth most common neoplastic disease worldwide. Two identified risk contributors are consumption of tobacco and alcohol. Among all other potential etiological factors, diet has long been recognized to play an important role in the development of cancers of the UADT. Data from a multi-centre, hospital-based case-control study conducted in Brazil were used to assess the association of dietary intake with the risk of cancers of the UADT. Dietary assessment was made in terms of estimated intake of nutrients, specific foods and food groups. After adjusting for the effects of alcohol and tobacco consumption as well as empirical confounders, protective effects against cancer of the mouth (Odds Ratio (OR) = 0.61, 95% confidence interval (95% CI): 0.4--1.0) and the pharynx (OR = 0.51, 95%CI: 0.3--0.9) were found for consumption of citric fruits. (Abstract shortened by UMI.)
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

He, Hua, and 何華. "Anti-tumor mechanisms of cyclooxygenase inhibitors and a c-Jun-N-terminal kinase inhibitor in gastrointestinal cancers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B30075245.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Collard, Olivier Conroy Philippe. "Chirurgie des métastases hépatiques dans les cancers colo-rectaux étude rétrospective de 84 patients opérés au Centre Alexis Vautrin et en chirurgie digestive générale, CHU de Nancy de 1985 à 2000 /." [S.l.] : [s.n.], 2002. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2002_COLLARD_OLIVIER.pdf.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Digestive cancers"

1

P, Griffin-Sobel Joyce, and Oncology Nursing Society, eds. Gastrointestinal cancers. Oncology Nursing Society, 2007.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Takahashi, Toshio, ed. Recent Advances in Management of Digestive Cancers. Springer Japan, 1993. http://dx.doi.org/10.1007/978-4-431-68252-3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

A, Ajani Jaffer, and Hoff Paulo M, eds. Atlas of gastrointestinal cancers. Current Medicine, 2006.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

K, Rustgi Anil, ed. Gastrointestinal cancers: Biology, diagnosis, and therapy. Lippincott-Raven, 1995.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

1935-, Takahashi T., ed. Recent advances in management of digestive cancers: Proceedings of UICC Kyoto International Symposium on Recent Advances in Management of Digestive Cancers, March 31-April 2, 1993. Springer-Verlag, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

K, Rustgi Anil, and Crawford James M. 1954-, eds. Gastrointestinal cancers: A companion to Sleisenger and Fordtran's gastrointestinal and liver disease. Saunders, 2003.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

National Cancer Institute (U.S.), ed. Biology of and novel therapeutic approaches for epithelial cancers of the aerodigestive tract: Proceedings of a conference held at Steamboat Springs, Colorado, April 1-7, 1991. National Cancer Institute, 1992.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Keystone Symposia on Molecular and Cellular Biology (1991 Steamboat Springs, Colo.). Biology of and novel therapeutic approaches for epithelial cancers of the aerodigestive tract: Proceedings of a conference held at Steamboat Springs, Colorado, April 1-7, 1991. National Cancer Institute, 1992.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Rougier, Philippe, Emmanuel Mitry, Sophie Dominguez-Tinajero, and Julien Taïeb. Les cancers digestifs. Springer Paris, 2006. http://dx.doi.org/10.1007/2-287-30874-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

J, Belcastro V., and Dobelbower Ralph R, eds. Gastrointestinal cancer: Radiation therapy. Springer-Verlag, 1990.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Digestive cancers"

1

Pujol, B., B. Napoléon, and L. Palazzo. "Cancers du pancréas." In Écho-endoscopie digestive. Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-287-99164-6_28.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Bories, E. "Cancers de l’anus." In Écho-endoscopie digestive. Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-287-99164-6_43.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

des Guetz, G., and P. Wind. "Urgences en cancérologie digestive." In Les cancers digestifs. Springer Paris, 2006. http://dx.doi.org/10.1007/2-287-30874-1_18.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Panzini, B., and P. Poitras. "Genes and Digestive Cancers." In The Digestive System: From Basic Sciences to Clinical Practice. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-98381-9_25.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Bécouarn, Y. "Osseous metastases of digestive cancers." In Vertebral metastases. Springer Paris, 2002. http://dx.doi.org/10.1007/978-2-8178-0757-7_16.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Heath, Amy. "Cancers of the Digestive System." In Radiation Therapy Study Guide. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3258-0_15.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Seely, S. "Cancers of the Digestive Tract." In Diet-Related Diseases. Routledge, 2022. http://dx.doi.org/10.1201/9781003284369-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Blows, William T. "Cancers of the Digestive System." In The Biological Basis of Cancer, 2nd ed. Routledge, 2025. https://doi.org/10.4324/9781003389125-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Sepulveda, Jorge L. "Serological Markers of Digestive Tract Cancers." In Molecular Pathology Library. Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-6015-2_15.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Stephens, Frederick O., and Karl Reinhard Aigner. "Cancers of the Digestive System (Alimentary Tract)." In Basics of Oncology. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-92925-3_13.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Digestive cancers"

1

Zeng, Tao, Xiangtian Yu, and Chengming Zhang. "IDDF2019-ABS-0120 Pan-cancer study of progressive protein signatures for digestive cancers." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.29.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Nogueira, Leticia, Amanda Cross, Neal Freedman, Gabriel Lai, Felipe Castro, and Jill Koshiol. "Abstract 4804: Gallstones, cholecystectomy, and risk of digestive system cancers." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4804.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Wheeler, David A., Marie-Claude Gingras, Ronald Cotton, et al. "Abstract 2218: Whole exome DNA sequencing in human cancers of the digestive system." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2218.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Moullec, A., E. Bories, JP Ratone, et al. "L'ampullectomie endoscopique peut elle être curative pour les cancers ampullaires? Résultats d'une étude rétrospective monocentrique." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680960.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Morabit, S., H. Seddik, F. Bouhamou, et al. "Drainage biliaire endoscopique dans les cancers bilio-pancréatiques: résultats et facteurs associés à propos de 105 cas." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680885.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Hoibian, S., F. Caillol, A. Autret, et al. "Apport de l'echoendoscopie dans la prise en charge chirurgicale des cancers de l'estomac et de la jonction oesogastrique." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680881.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Koh, Benjamin, Darren Jun-Hao Tan, Cheng-Han Ng, et al. "IDDF2023-ABS-0012 Gastrointestinal cancers are the leading cause of young onset cancer in the United States." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10–11 June 2023. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2023. http://dx.doi.org/10.1136/gutjnl-2023-iddf.159.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Mutalib, Nurul-Syakima Ab, Ryia Illani Mohd Yunos, Najwa Farhah Mohd Yusof, et al. "IDDF2019-ABS-0312 The landscape of recurrent noncoding mutations in colorectal cancers." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.70.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

LiYa, Huang. "IDDF2019-ABS-0057 The clinical follow-up analysis of 127 pancreatic cancers patients." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.131.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Yu, Haiying, Baljendra Kapoor, and Gordan McLennan. "Advanced Imaging and Navigation Tools in Minimally Invasive Management of Liver Cancers." In Abstracts of 5th Annual Meeting of the American Society of Digestive Disease Interventions. Thieme Medical Publishers, 2019. http://dx.doi.org/10.1055/s-0039-1689017.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Digestive cancers"

1

Huang, Lumi, Lihui Chen, and Yiming Wang. Nestin and the survival of patients with digestive tract cancers. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.8.0087.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Wu, Bo, Jingting Liu, Chaodan Shao, Dongli Yu, and Jianhua Liao. CALLY Index as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.2.0043.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Yu, Dongli, Jingting Liu, Chunyan Meng, Baoqing Liu, and Jianhua Liao. Pan-immune-inflammation value as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.9.0087.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Xia, Zhiyu, Yufei Wang, Fu Liu, et al. Different effects of miRNA-499 polymorphism on digestive tract cancers susceptibility in eastern and western China:a meta-analysis and trial sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0006.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Meng, Chunyan, Jingting Liu, Jun Cheng, Bo Wu, and Jianhua Liao. Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Digestive System Cancers: a Systematic Review and Meta-Analysis of 31 Studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.1.0063.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

F. Al-Sanea, Hamad. Evaluation of Recent Surgical Updates Regarding Diagnosis and Management of Diverticulitis. Science Repository, 2024. http://dx.doi.org/10.31487/j.jsr.2024.01.01.

Der volle Inhalt der Quelle
Annotation:
Diverticulosis occurs when small, bulging pouches (diverticula) develop in your digestive tract. When one or more of these pouches become inflamed or infected, the condition is called diverticulitis. Diverticula are small, bulging pouches that can form in the lining of your digestive system, although it was rare before the 20th century, diverticular disease is now one of the most common health problems in the western world. It’s a group of conditions that can affect your digestive tract. The most serious type of diverticular disease is diverticulitis. It can cause uncomfortable symptoms and, in some cases, serious complications. If left untreated, these complications can cause long-term health problems. Read on to learn more about diverticulitis, including its causes, symptoms, treatment options, and how your diet might affect your risk of developing it. Objective: In this paper, our main focus was on diverticulitis and surgical intervention, and only relevant studies were discussed. Methodology: PubMed database was used for articles selection, and papers on diverticulitis were obtained and reviewed. Conclusion: Colonoscopy is best avoided in acute and uncomplicated diverticulitis. Classically, it is a surgical disease but uncomplicated cases can often be managed conservatively. Follow up of treated diverticulitis occurs after four weeks via colonoscopy, in selected cases assessing the risk of developing colonic cancer. Novel therapies are under-studied and are probable replacements for surgical intervention.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Bischof, Patricia, and Margaret Wexler. Fibre, the gut microbiome and breast cancer. Breast Cancer UK, 2023. https://doi.org/10.71450/64900277.

Der volle Inhalt der Quelle
Annotation:
All studies reviewed in this briefing have found a diet high in fibre is linked to a decreased breast cancer risk. The British Nutrition Foundation recommends the average adult consumes at least 30g of fibre per day. Dietary fibre has many effects on the body, especially on digestion and the composition of microorganisms in your gut. A varied diet rich in fibre, such as the Mediterranean diet – which includes high consumption of whole grains – supports a diverse and stable gut microbiome (the total population of gut microorganisms) and contributes significantly to gut health. Fibre may help prevent breast cancer through several proposed mechanisms which include preventing the reabsorption of oestrogens from the gut into the blood; binding oestrogen and thus increasing faecal excretion; and helping to reduce the risk of becoming overweight or obese.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie